Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

被引：0
|
作者：
Michele R. Wilson
Matt Wasserman
Taj Jadavji
Maarten Postma
Marie-Claude Breton
Francois Peloquin
Stephanie R. Earnshaw
Cheryl McDade
Heather L. Sings
Raymond Farkouh
机构：
[1] RTI Health Solutions,Departments of Pediatrics, Microbiology, Immunology, and Infectious Diseases, Faculty of Medicine, Cumming School of Medicine
[2] Pfizer Inc.,Department of Pharmacy
[3] University of Calgary,Research Institute of Science in Healthy Aging and healthcaRE (SHARE)
[4] University of Groningen,undefined
[5] University of Groningen,undefined
[6] University Medical Center Groningen (UMCG),undefined
[7] Pfizer Canada Inc.,undefined
[8] Pfizer Inc.,undefined
来源：
Infectious Diseases and Therapy | 2018年 / 7卷
关键词：
Cost-effectiveness; Health economics; Pneumococcal disease; Vaccination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 543
页数：4
相关论文
共 50 条
  • [1] Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"
    Wilson, Michele R.
    Wasserman, Matt
    Jadavji, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie R.
    McDade, Cheryl
    Sings, Heather L.
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 539 - 543
  • [2] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Michele Wilson
    Matt Wasserman
    Taj Jadavi
    Maarten Postma
    Marie-Claude Breton
    Francois Peloquin
    Stephanie Earnshaw
    Cheryl McDade
    Heather Sings
    Raymond Farkouh
    Infectious Diseases and Therapy, 2018, 7 : 353 - 371
  • [3] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Wilson, Michele
    Wasserman, Matt
    Jadavi, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie
    McDade, Cheryl
    Sings, Heather
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (03) : 353 - 371
  • [4] Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018
    McGirr, Ashleigh
    Iqbal, Shehzad M.
    Olbrecht, Jan
    Varghese, Lijoy
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 535 - 538
  • [5] Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
    Ashleigh McGirr
    Shehzad M. Iqbal
    Jan Olbrecht
    Lijoy Varghese
    Infectious Diseases and Therapy, 2018, 7 : 535 - 538
  • [6] COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
    Whillans, F.
    Kwan, H.
    Strutton, D. R.
    Earnshaw, S. R.
    Farkouh, R.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [7] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease
    Theilacker, Christian
    Hilton, Betsy
    Jiang, Qin
    Gessner, Bradford D.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1641 - 1642
  • [8] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Reply
    Naucler, Pontus
    Galanis, Ilias
    Morfeldt, Eva
    Darenberg, Jessica
    Ortqvist, Ake
    Henriques-Normark, Birgitta
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1642 - 1643
  • [9] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
    Ansaldi, Filippo
    Pugh, Sarah
    Amicizia, Daniela
    Di Virgilio, Roberto
    Trucchi, Cecilia
    Orsi, Andrea
    Zollo, Alessandro
    Icardi, Giancarlo
    PATHOGENS, 2020, 9 (02):
  • [10] The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease
    Principi, Nicola
    Esposito, Susanna
    EXPERT REVIEW OF VACCINES, 2015, 14 (10) : 1359 - 1366
12345